CERC Cerecor Inc.

1.20
+0.02  (2%)
Previous Close 1.18
Open 1.23
Price To book 1.41
Market Cap 31265828
Shares 26,054,857
Volume 74,881
Short Ratio 2.27
Av. Daily Volume 378,047

SEC filingsSee all SEC filings

  1. 424B3 - Prospectus [Rule 424(b)(3)] 171210972
  2. 8-K - Current report 171210924
  3. 424B3 - Prospectus [Rule 424(b)(3)] 171180809
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171180668
  5. 8-K - Current report 171178368

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 trial planned.
CERC-501
Major depressive disorder (MDD)
Phase 2 top-line data released December 5, 2016 - endpoint not met.
CERC-501
Smoking cessation
Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.
CERC-301
Major depressive disorder (MDD)

Latest News

  1. Corporate News Blog - Cerecor Acquired TRx Pharmaceuticals
  2. Is It The Right Time To Buy Cerecor Inc (CERC)?
  3. Baltimore pharmaceutical company acquiring North Carolina firm for at least $27 million
  4. Cerecor Announces Leadership Changes
  5. Cerecor Acquires TRx Pharmaceuticals
  6. Best Undervalued Stock Picks
  7. CERC: With An Infusion of Non-dilutive Capital, Cerecor Ready to Move the Pipeline Forward
  8. What does Cerecor Inc’s (CERC) Balance Sheet Tell Us Abouts Its Future?
  9. Cerecor Inc. Reports Third Quarter 2017 Financial Results
  10. Cerecor, Inc. Regains Compliance with NASDAQ Minimum Bid Price Requirement
  11. Dilution Ahead For Cerecor Inc (CERC) Shareholders?
  12. CERC: Sells CERC-501 for $25 Million; Company Currently Trading Below Cash Value
  13. What Shareholders Should Make of the Johnson & Johnson-Cerecor Situation
  14. Cerecor, Inc. :CERC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
  15. Cerecor Inc. Announces Retirement of Dr. Uli Hacksell as President and Chief Executive Officer
  16. Cerecor Inc. Reports Second Quarter 2017 Financial Results
  17. Cerecor Announces Divestiture of CERC-501 to Janssen Pharmaceuticals, Inc.
  18. Cerecor to present at the American Society for Clinical Psychopharmacology Conference
  19. Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
  20. CERC: Encouraging Results from Proof-of-Concept Study of CERC-501 in MDD

SEC Filings

  1. 424B3 - Prospectus [Rule 424(b)(3)] 171210972
  2. 8-K - Current report 171210924
  3. 424B3 - Prospectus [Rule 424(b)(3)] 171180809
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171180668
  5. 8-K - Current report 171178368
  6. 424B3 - Prospectus [Rule 424(b)(3)] 171146022
  7. 8-K - Current report 171145979
  8. 424B3 - Prospectus [Rule 424(b)(3)] 171142122
  9. 8-K/A [Amend] - Current report 171142094
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171061465